This represents a new revenue stream for Khiron and positions its European team to execute on its German medical strategy. Leveraging Nimbus Health’s large distribution network and Khiron’s ongoing investments in physician education, the Canadian listed firm with Colombian operations will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis.

The launch product is Khiron’s 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis.

“Since signing our distribution agreement with Nimbus Health in 2020, the company’s European Sales and Marketing teams have been actively educating doctors and raising awareness for our products. We are excited to launch our portfolio with Khiron 1/14, a product that covers unmet medical need in the German market. As we continue to expand our presence in the UK and Germany, we will leverage our clinical expertise from Colombia to provide the EU market with additional cannabis-based medicinal products,” said Tejinder Virk, President of Khiron Europe.

Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented, “I would like to thank our European team for their unwavering perseverance over the past few months; their efforts have allowed us to achieve this significant milestone despite the challenges of the global pandemic and Germany’s strict regulatory environment. With all permits in place and product now available for sale, we look forward to increasing our presence in this growing market with over 60,000 medical cannabis patients and a population of over 82 million people. We are already developing additional cannabis-based medicinal products from our certified strains recently imported from Colombia to improve access and product selection for German patients.”

Avianca indicated that the restrictions were necessitated by “the constant restrictions in different countries in terms of limitation of the entry of tourists, operational reductions, as well as mobility within cities, and the high uncertainty that passengers still have.”

Passengers are advised to visit the Avianca website and contact the air carrier to confirm individual details.

Suspended flights include those from Bogotá, Colombia to and from:

• Washington, DC
• Los Angeles
• Orlando
• Fort Lauderdale
• London
• Barcelona
• Curaçao
• San Juan, Puerto Rico
• Asunción
• La Paz, Bolivia
• Santa Crúz, Bolivia
• Guatemala City
• Panamá City

Also suspended are the following flights:

• Cali – Medellín – Madríd
• Guatemala City – Tegucigalpa
• Guatemala City – Los Angeles
• Panamá City – San José, Costa Rica
• San Salvador – Dallas
• San Salvador – Houston
• San Salvador – Miami
• San Salvador – Toronto
• San Salvador – México City
• Quito – Galapagos Islands
• Quito – El Coca
• San Pedro Sula – Miami

Avianca says it hopes to resume flights in April to Curaçao, Orlando, Guatemala City, and Los Angeles from Bogotá, and San Salvador to Houston, Toronto and México City.

The airline is currently undergoing Chapter 11 Bankruptcy reorganization in US Federal Court.